Communicators

are winners!

Top News

15.02.2025
Vancouver, Canada - February 14, 2025 - Onco-Innovations Limited (CSE: ONCO) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its licensed nanoparticle formulation of a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the “Technology” or “PNKP Compound”), which has shown effectiveness in slowing the growth of colorectal cancer (CRC) tumours when used as a standalone treatment and in combination with radiation therapy, based on findings from June[i] and December[ii] 2021 studies led by researchers at the University of Alberta. Onco-Innovations ... [ more ]